ANI Pharmaceuticals (ANIP) news
Recent news
Ani Pharma: Positive phase 4 clinical trial results
Ani Pharma has announced the completion of its phase 4 clinical trial for a novel therapeutic compound, with results indicating a statistically significant improvement in patient outcomes compared to the standard of care. The trial, conducted across multiple international sites, enrolled over 1,200…
AInvest Wire · 3d agoAni Pharmaceuticals announces the FDA approval of everolimus tablets for oral suspension
AInvest Wire · Sep 23, 2026ANI Pharmaceuticals appoints Henry Gosebruch to board of directors
AInvest Wire · Aug 24, 2026ANI Pharmaceuticals shares down 9% after co forecasts 2026 revenue below estimates
AInvest Wire · Aug 7, 2026ANI Pharmaceuticals shares down 8.1% premarket after co forecasts 2026 revenue below estimates
ANI Pharmaceuticals (NASDAQ:ANIP) shares fell 8.1% in premarket trading on August 7, 2026, following the company’s announcement of 2026 revenue guidance that fell below analyst expectations. The stock had previously surged more than 10% after the company released strong preliminary 2025 results and…
AInvest Wire · Aug 7, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.